The potential effects of introducing microneedle patch vaccines into routine vaccine supply chains.

Abstract

BACKGROUND\nMicroneedle patch (MNP) technology is designed to simplify the process of vaccine administration; however, depending on its characteristics, MNP technology may provide additional benefits beyond the point-of-use, particularly for vaccine supply chains.\n\n\nMETHODS\nUsing the HERMES modeling software, we examined replacing four routine vaccines - Measles-containing vaccine (MCV), Tetanus toxoid (TT), Rotavirus (Rota) and Pentavalent (Penta) - with MNP versions in the routine vaccine supply chains of Benin, Bihar (India), and Mozambique.\n\n\nRESULTS\nReplacing MCV with an MNP (5\u202fcm3-per-dose, 2-month thermostability, current single-dose price-per-dose) improved MCV availability by 13%, 1% and 6% in Benin, Bihar and Mozambique, respectively, and total vaccine availability by 1% in Benin and Mozambique, while increasing the total cost per dose administered by $0.07 in Benin, $0.56 in Bihar and $0.11 in Mozambique. Replacing TT with an MNP improved TT and total vaccine availability (3% and <1%) in Mozambique only, when the patch was 5\u202fcm3 and 2-months thermostable but increased total cost per dose administered by $0.14. Replacing Rota with an MNP (at 5-15\u202fcm3-per-dose, 1-2\u202fmonth thermostable) improved Rota and total vaccine availability, but only improved Rota vaccine availability in Bihar (at 5\u202fcm3, 1-2\u202fmonths thermostable), while decreasing total vaccine availability by 1%. Finally, replacing Penta with an MNP (at 5\u202fcm3, 2-months thermostable) improved Penta vaccine availability by 1-8% and total availability by <1-9%.\n\n\nCONCLUSIONS\nAn MNP for MCV, TT, Rota, or Penta would need to have a smaller or equal volume-per-dose than existing vaccine formulations and be able to be stored outside the cold chain for a continuous period of at least two months to provide additional benefits to all three supply chains under modeled conditions.